Report of Foreign Issuer (6-k)
October 10 2019 - 8:06AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
Report of Foreign Private Issuer
Pursuant to Rule 13a-16 or 15d-16 of
the Securities Exchange Act of 1934
For the month of October 2019
Commission File Number: 001-36622
PROQR THERAPEUTICS N.V.
Zernikedreef 9
2333 CK Leiden
The Netherlands
Tel: +31 88 166 7000
(Address, Including ZIP Code, and Telephone Number,
Including Area Code, of Registrants Principal Executive Offices)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F x Form 40-F o
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): o
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): o
On October 10, 2019, ProQR Therapeutics N.V. (the Company) issued a press release titled, ProQR Announces Positive Top-Line Results from the Phase 1/2 Study of Sepofarsen in LCA10 Patients. A copy of this press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference. The Company hereby incorporates by reference the information contained herein into the Companys registration statement on Form F-3 (File No. 333-228251).
In addition, the Company presented top-line results from its Phase 1/2 clinical trial of Sepofarsen in LCA10 patients using a webcasted conference call. A copy of the presentation is attached hereto as Exhibit 99.2, which is intended to be furnished and shall not be deemed to be filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the Exchange Act), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.
2
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
|
PROQR THERAPEUTICS N.V.
|
|
|
|
|
Date: October 10, 2019
|
By:
|
/s/ Smital Shah
|
|
|
Smital Shah
|
|
|
Chief Financial Officer
|
3
INDEX TO EXHIBITS
Number
|
|
Description
|
|
|
|
99.1
|
|
Press Release dated October 10, 2019.
|
99.2
|
|
Presentation for webcasted conference call.
|
4
ProQR Therapeutics NV (NASDAQ:PRQR)
Historical Stock Chart
From Mar 2024 to Apr 2024
ProQR Therapeutics NV (NASDAQ:PRQR)
Historical Stock Chart
From Apr 2023 to Apr 2024